BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
Go back to BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting| (NASDAQ: BTAI) | Delayed: 1.30 +0.10 (8.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.20 | 52 Week High | $ | |||
| Open | $1.20 | 52 Week Low | $ | |||
| Day High | $1.30 | P/E | N/A | |||
| Day Low | $1.20 | EPS | $ | |||
| Volume | 779,734 | |||||
